NDC product
ganciclovir sodium
NDC 70436-231 · Slate Run Pharmaceuticals, LLC
Key facts
| Product NDC | 70436-231 |
|---|---|
| Proprietary name | ganciclovir sodium |
| Nonproprietary name | ganciclovir sodium |
| Substances | GANCICLOVIR SODIUM |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRAVENOUS |
| Labeler | Slate Run Pharmaceuticals, LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA204204 |
| Pharmacologic classes | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], DNA Polymerase Inhibitors [MoA], Nucleoside Analog Antiviral [EPC], Nucleoside Analog [EXT] |
| Marketing start | Jan 1, 2019 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: